title: High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
abstract: OBJECTIVE
  Immunotherapy with Bacillus Calmette Guerin (BCG) has been widely used recently as primary option for treatment of high grade superficial (G3T1) carcinoma of the bladder. We describe our long term experience of therapy of G3T1 bladder cancer.
  
  
  METHODS
  From January 1982 to December 2000, 785 patients were diagnosed with superficial bladder cancer. All patients underwent preoperative CT scan and transurethral resection of the bladder. Eighty-six patients (11%) had histological high grade superficial bladder cancer infiltrating the lamina propria. This group was treated with the following schedule of BCG Pasteur strain plus maintenance. Four cycles BCG, 6 instillations per cycle, first cycle weekly x 6, second cycle every 2 weeks x 6, third cycle monthly x 6, fourth cycle (maintenance) every 3 months x 6 instillations.
  
  
  RESULTS
  The median follow-up is 91 months (30-197 months). The overall recurrence rate was 35% (30/86). The median time to recurrence was 29 months (5-128 months). Of these patients, 12 (14%) had progression at a median follow-up of 16 months (range 8-58 months). Cystectomy was needed in 8 (9%) patients. Death due to disease occurred in 5/86 (6%) patients. One patient died due to adenocarcinoma at the ureterosigmoidostomy site. Sixty-four (74%) patients are alive at a median follow-up of 71 months (range 28-197 months). Sixty patients (70%) are alive with an intact bladder.
  
  
  CONCLUSIONS
  Treatment with BCG is a feasible conservative therapy for patients with primary G3T1 transitional bladder cancer. Long term results of BCG treatment are excellent. Cystectomy shouldn't be considered first line treatment for high grade superficial carcinoma of the bladder.
authors.affiliation: Vincenzo Pansadoro Foundation and San Giovanni Hospital, Rome, Italy. paoloemiliozzi@hotmail.com
authors.forename: V
authors.initials: V
authors.lastname: Pansadoro
authors.forename: P
authors.initials: P
authors.lastname: Emiliozzi
authors.forename: F
authors.initials: F
authors.lastname: depaula
authors.forename: P
authors.initials: P
authors.lastname: Scarpone
authors.forename: M
authors.initials: M
authors.lastname: Pizzo
authors.forename: G
authors.initials: G
authors.lastname: Federico
authors.forename: M
authors.initials: M
authors.lastname: Martini
authors.forename: A
authors.initials: A
authors.lastname: Pansadoro
authors.forename: C N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000628:therapy*